Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Stroke Prevention Therapy Is Low Among AF Patients

August 29, 2011 10:59 am | News | Comments

New data shows that one in three patients with atrial fibrillation who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists – medicines known to significantly lower stroke risk.

TOPICS:

Icagen Says Pfizer Won't Raise Share Offer

August 29, 2011 10:47 am | News | Comments

Icagen Inc. urged its shareholders to support Pfizer Inc.'s bid to acquire the company, saying Pfizer will not raise its offer. Icagen received a letter from Pfizer on August 26, which reiterated that the bid of $6 per share is Pfizer's "best and final price."

TOPICS:

Sirtex Medical Posts Record Result

August 29, 2011 10:44 am | News | Comments

Sirtex Medical Limited announced revenue from the sales of goods increased 9% to $70.3 million for the period ending June 30, 2011. Dose sales increased 19% from 4,171 doses to 4,977 doses worldwide.

TOPICS:
Advertisement

NovAliX, Galapagos Collaborate on OA Research

August 29, 2011 10:35 am | News | Comments

NovAliX has collaborated with Galapagos for osteoarthritis. Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.

TOPICS:

Genetic Technologies Maiden Profit for 2011

August 29, 2011 10:28 am | News | Comments

Genetic Technologies Limited announced its maiden profit for the financial year ended on June 30, 2011. The company reported a net profit for the period of $950,000 and positive net cash flows of $2.34 million.

TOPICS:

Clavis Pharma Expands Clavela Study

August 29, 2011 10:23 am | News | Comments

Clavis Pharma will expand its Phase 3 Clavela study, investigating elacytarabine in patients with late-stage acute myeloid leukaemia with the statistical power of the study increasing from 80% to 90%.

TOPICS:

Removeable Labels

August 29, 2011 9:07 am | Product Releases | Comments

CILS-9100R ultra durable removable labels provide high-strength bonding to all plastic/glassware and can be easily removed at any time, leaving no sticky adhesive residue.

TOPICS:

DNA Visualization Dye

August 29, 2011 9:00 am | Product Releases | Comments

Amresco’s Ready One-Step RT-PCR Kit provides efficiency, quality, and safety by mixing the convenience of a one-step RT-PCR kit with loading buffer and a safe DNA visualization dye.

TOPICS:
Advertisement

Agilent and CNU Partnering on Glycomics

August 29, 2011 8:41 am | News | Comments

Agilent Technologies Inc. and Chungnam National University announced an agreement to develop new applications, methods, technologies, and software tools in the field of glycomics, the study of complex sugars.

TOPICS:

Nucynta Gets Nod from FDA

August 29, 2011 8:31 am | News | Comments

Johnson & Johnson said the Food and Drug Administration has approved an extended-release version of the painkiller Nucynta. Nucynta is an oral medication taken twice daily to manage moderate-to-severe chronic pain in adults.

TOPICS:

Valeant Pharma Adds $300M to Repurchase Authority

August 29, 2011 8:00 am | News | Comments

The Canadian drugmaker Valeant Pharmaceuticals International Inc. said it approved an increase of $300 million in its program to repurchase shares, senior notes, and other securities.

TOPICS:

AIC246 Granted Fast Track Status

August 29, 2011 7:53 am | News | Comments

AiCuris announced that the Food and Drug Administration (FDA) of the United States has granted Fast Track designation for one of the company’s lead drugs, AIC246, an inhibitor of the human cytomegalovirus.

TOPICS:

Sabotage Suspected in Painkiller Mix-up

August 29, 2011 7:50 am | News | Comments

The British company that makes Nurofen Plus painkillers recalled the tablets because of suspected sabotage involving the use of drugs used to treat psychosis.

TOPICS:

Drug Cuts Stroke, Death Risks

August 29, 2011 7:46 am | News | Comments

Developers of an experimental drug that's part of a new generation of anticlotting medicines expected to be blockbusters said that in a key patient study, apixaban significantly cut the risks of stroke, major bleeding, and death.

TOPICS:

FDA OKs Pfizer Cancer Treatment

August 29, 2011 7:37 am | by Matthew Perrone | News | Comments

The Food and Drug Administration has approved a new Pfizer drug for a subset of lung cancer patients with a particular genetic mutation. The twice-a-day pill, called Xalkori, is part of a new wave of personalized medications.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading